Sex Differences in Survival from Neuroendocrine Neoplasia in England 2012-2018: A Retrospective, Population-Based Study

被引:13
作者
White, Benjamin E. [1 ]
Russell, Beth [2 ]
Remmers, Sebastiaan [3 ]
Rous, Brian [4 ]
Chandrakumaran, Kandiah [1 ]
Wong, Kwok F. [4 ]
Van Hemelrijck, Mieke [2 ]
Srirajaskanthan, Rajaventhan [5 ]
Ramage, John K. [1 ]
机构
[1] Hampshire Hosp NHS Fdn Trust, Basingstoke & North Hampshire Hosp, Basingstoke RG24 9NA, England
[2] Kings Coll London, Sch Canc & Pharmaceut Sci, Translat Oncol & Urol Res, London WC2R 2LS, England
[3] Univ Med Ctr Rotterdam, Erasmus MC Canc Inst, Dept Urol, NL-3015 GD Rotterdam, Netherlands
[4] NHS Digital, 7&8 Wellington Pl, Leeds LS1 4AP, England
[5] Kings Coll Hosp London, Kings Hlth Partners ENETS Ctr Excellence, London SE5 9RS, England
关键词
neuroendocrine tumour; neuroendocrine neoplasia; carcinoid; epidemiology; survival; incidence; predictors of survival; TUMORS; CONSENSUS; EXPRESSION; RECEPTOR; PROGNOSIS;
D O I
10.3390/cancers15061863
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary We conducted a retrospective, population-based study comparing overall survival (OS) between males and females with neuroendocrine neoplasia (NEN). In total, 14,834 cases of NEN recorded in England's National Cancer Registry and Analysis Service (NCRAS)), were analysed. Multivariable analysis, restricted mean survival time and mediation analysis were performed. Females displayed increased survival irrespective of the stage, morphology or level of deprivation, which was statistically significant in NEN of the lung, pancreas, rectum and stomach (p < 0.001). Stage of tumour mediated improved survival in stomach, lung, and pancreatic NEN but not in rectal NEN. Females diagnosed with NEN tend to survive longer than males, and stage at presentation only accounts for part of this effect. Future research in NEN, as well as prognostication and treatment, should consider sex as an important factor. Pre-clinical studies have suggested sex hormone signalling pathways may influence tumorigenesis in neuroendocrine neoplasia (NEN). We conducted a retrospective, population-based study to compare overall survival (OS) between males and females with NEN. A total of 14,834 cases of NEN diagnosed between 2012 and 2018, recorded in England's National Cancer Registry and Analysis Service (NCRAS), were analysed. The primary outcome was OS with 5 years maximum follow-up. Multivariable analysis, restricted mean survival time and mediation analysis were performed. Appendiceal, pulmonary and early-stage NEN were most commonly diagnosed in females; stomach, pancreatic, small intestinal, colonic, rectal and later-stage NEN were more often diagnosed in males. Females displayed increased survival irrespective of the stage, morphology or level of deprivation. On average, they survived 3.62 (95% CI 1.73-5.90) to 10.26 (6.6-14.45) months longer than males; this was statistically significant in NEN of the lung, pancreas, rectum and stomach (p < 0.001). The stage mediated improved survival in stomach, lung, and pancreatic NEN but not in rectal NEN. The reasons underlying these differences are not yet understood. Overall, females diagnosed with NEN tend to survive longer than males, and the stage at presentation only partially explains this. Future research, as well as prognostication and treatment, should consider sex as an important factor.
引用
收藏
页数:13
相关论文
共 46 条
  • [1] Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms A Population-Based Study
    Abdel-Rahman, Omar
    Fazio, Nicola
    [J]. PANCREAS, 2021, 50 (05) : 727 - 731
  • [2] Immunohistochemical Expression and Prognostic Value of ER, PR and HER2/neu in Pancreatic and Small Intestinal Neuroendocrine Tumors
    Arnason, Thomas
    Sapp, Heidi L.
    Barnes, Penelope J.
    Drewniak, Magdalena
    Abdolell, Mohamed
    Rayson, Daniel
    [J]. NEUROENDOCRINOLOGY, 2011, 93 (04) : 249 - 258
  • [3] Barros M, 2019, ANN ONCOL, V30, P573
  • [4] The EUROCARE Study: strengths, limitations and perspectives of population-based, comparative survival studies
    Berrino, F.
    [J]. ANNALS OF ONCOLOGY, 2003, 14 : V9 - V13
  • [5] Sexual Dimorphism in Small-intestinal Neuroendocrine Tumors: Lower Prevalence of Mesenteric Disease in Premenopausal Women
    Blazevic, Anela
    Iyer, Anand M.
    Van Velthuysen, Marie-Louise F.
    Hofland, Johannes
    Oudijk, Lindsey
    de Herder, Wouter W.
    Hofland, Leo J.
    Feelders, Richard A.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (05) : E1969 - E1975
  • [6] Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours
    Blazevic, Anela
    Brabander, Tessa
    Zandee, Wouter T.
    Hofland, Johannes
    Franssen, Gaston J. H.
    van Velthuysen, Marie-Louise F.
    Feelders, Richard A.
    De Herder, Wouter W.
    [J]. CANCERS, 2021, 13 (03) : 1 - 8
  • [7] Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours
    Blazevic, Anela
    Zandee, Wouter T.
    Franssen, Gaston J. H.
    Hofland, Johannes
    van Velthuysen, Marie-Louise F.
    Hofland, Leo J.
    Feelders, Richard A.
    de Herder, Wouter W.
    [J]. ENDOCRINE-RELATED CANCER, 2018, 25 (03) : 245 - 254
  • [8] Brierley J., 2017, TNM Classfication of Malignant Tumors, V8th
  • [9] Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
    Caplin, M. E.
    Baudin, E.
    Ferolla, P.
    Filosso, P.
    Garcia-Yuste, M.
    Lim, E.
    Oberg, K.
    Pelosi, G.
    Perren, A.
    Rossi, R. E.
    Travis, W. D.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (08) : 1604 - 1620
  • [10] Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study
    Cetinkaya, Raziye Boyar
    Aagnes, Bjarte
    Myklebust, Tor Age
    Thiis-Evensen, Espen
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (06) : 1139 - 1147